BamSEC and AlphaSense Join Forces
Learn More

BioCryst Pharmaceuticals Inc. – Material Contracts

NASDAQ: BCRX    
Share price (7/2/26): $9.84    
Market cap (7/2/26): $2.501 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 22 pages BioCryst Pharmaceuticals, Inc. Stock Incentive Plan
12/34/56
EX-10.3
from 10-Q 19 pages March 18, 2026 via Electronic Mail 1. Term of Employment
12/34/56
EX-10.57
from 10-K 6 pages Joinder Agreement
12/34/56
EX-10.56
from 10-K 6 pages Joinder Agreement
12/34/56
EX-10.48
from 10-K 3 pages BioCryst Pharmaceuticals, Inc. Equity Award Retirement Policy Effective Date: July 1, 2024
12/34/56
EX-10.39
from 10-K 19 pages January 1, 2026 via Electronic Mail ([***]) 1. Term of Employment. 2. Basic Full-Time Compensation and Benefits
12/34/56
EX-10.38
from 10-K 20 pages Amended and Restated Employment Agreement
12/34/56
EX-10.34
from 10-K 7 pages December 16, 2025 via Electronic Mail ([***]) Charlie Gayer [***] [***] Dear Mr. Gayer,
12/34/56
EX-10.32
from 10-K 4 pages December 28, 2025 Jon Stonehouse [***] [***] Dear Mr. Stonehouse
12/34/56
EX-10.4
from 10-Q 9 pages Consulting Agreement
12/34/56
EX-10.3
from 10-Q 12 pages Material contract
12/34/56
EX-10.5
from 8-K 23 pages Trademark License Agreement Dated as of October 1, 2025 by and Between BioCryst Pharmaceuticals, Inc., as Licensor, and BioCryst Ireland Limited, as Licensee
12/34/56
EX-10.4
from 8-K 32 pages Transition Services Agreement Dated as of October 1, 2025 by and Between BioCryst Pharmaceuticals, Inc., as Seller, and BioCryst Ireland Limited, as Company
12/34/56
EX-10.3
from 8-K 35 pages Global Brand and Support Agreement Dated as of October 1, 2025 by and Between BioCryst Pharmaceuticals, Inc., as the Seller, and BioCryst Ireland Limited, as the Company
12/34/56
EX-10.2
from 8-K 32 pages Supply Agreement Dated as of October 1, 2025 by and Between BioCryst Pharmaceuticals, Inc., as Supplier, and BioCryst Ireland Limited, as Recipient
12/34/56
EX-10.1
from 8-K 30 pages Amended and Restated Ip Licence Agreement Dated as of October 1, 2025 by and Between BioCryst Pharmaceuticals, Inc., as the Licensor, and BioCryst Ireland Limited, as the Licensee
12/34/56
EX-10.4
from 10-Q 3 pages Second Amendment to Employment Agreement
12/34/56
EX-10.3
from 10-Q 20 pages Amended and Restated Employment Agreement
12/34/56
EX-10.2
from 10-Q 1 page Amendment to Consulting Agreement
12/34/56
EX-10.1
from 8-K 22 pages BioCryst Pharmaceuticals, Inc. Stock Incentive Plan
12/34/56